NGLFINE NGL Fine-Chem Q2 FY26 results (Jul–Sep 2025) and concall
NGL Fine Chem reported strong Q2 and H1 FY26 results driven by broad-based demand recovery in India and Asia, with significant growth in revenue and EBITDA. The company is making strategic progress in regulated markets, having filed its first API registration with the US FDA and expanding its European portfolio. While profitability was slightly impacted by increased costs and lower realizations, management is optimistic about future margin improvement as new capacities come online and regulated market sales commence, despite acknowledging ongoing pricing pressures and a cautious outlook on sus
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 29.0%, net profit up 0.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 93 | 89 | 95 | 104 | 120 +29% |
| EBITDA | 12 | 5 | 6 | 11 | 17 +42% |
| Net profit | 10 | 1 | 1 | 9 | 10 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
